Every clinical organization says it wants problems raised early. Most organizations behave in ways that guarantee the opposite.

The behaviors are rarely deliberate. A study manager reports a site enrollment problem and is immediately asked for a recovery plan, a root cause analysis, and a revised projection, all within the same conversation. The message received is that raising an issue…

All too often, the proposal that wins the bid is not the story that's actually executed.

CRO proposals are crafted like compelling movie trailers—tight narratives, confident timelines, reassuring team slides.  But somewhere between the bid defense and signing the contract, that narrative loses its operational spine.  What remains is a signed document that governs legally, but not operationally.

A contract should function as the…

Too many sponsor-CRO governance meetings turn into slide reviews.  We look at timelines, enrollment, protocol deviations, and data quality metrics, nod in agreement, and move on.  But if the metric doesn’t elicit a decision, an escalation, or a behavior, it’s just status reporting.

For biotech and emerging biopharma, effective governance is the mechanism that converts limited time, capital, and CRO capacity into accountable decisions and protected development timelines.

The metrics that matter are those tied to…

Phase 2 is where most emerging sponsors first feel the gap between what they can run and what the study requires. The site count rises, enrollment becomes a genuine risk rather than an assumption, and the data package starts carrying weight with the next investor.

It is also where CRO selection stops being a procurement exercise and starts being a development decision…

Sponsors regularly treat CRO and vendor selection as a sourcing exercise with a leadership rubber stamp at the end. The bid defense is scored, the pricing is compared, the recommendation goes up, and an executive signs. The structure looks rigorous. It frequently produces the wrong choice.

The problem is that the selection criteria that predict delivery success are largely invisible in a competitive bid process. Every CRO presents experienced leadership at the defense. Every CRO shows relevant…

When your CRO uses AI on your trial, you remain accountable for the results. Regulators will not accept "the vendor's algorithm did it" as an explanation for a missed safety signal or a flawed dataset. Sponsor oversight has to extend to the tools your vendors use, not just the people.

This is a quiet shift that many emerging sponsors have not noticed yet. CROs are embedding…

A clinical program running across North America, Europe, and Asia-Pacific creates leadership conditions that co-located management practices do not address. The obvious challenge is scheduling. The real challenges are subtler and more consequential.

Escalation norms differ substantially by region and organizational culture. A study coordinator in one country may flag a potential eligibility issue immediately and directly. A counterpart elsewhere may consider it inappropriate…

Inspection readiness is often treated like a final chapter, assembled when the story is nearly complete. In reality, it is the act of writing the story itself.

Too many organizations approach inspections as reconstruction: piecing together emails, minutes, and decisions after the fact, hoping the narrative holds. But regulators are not looking for a well-edited retrospective. They are looking for evidence of continuous, intentional oversight.

ICH E6(R3) reinforces a critical truth: while activities may be outsourced, accountability never is. Sponsors must demonstrate…

Most programs don’t fall off track because of bad science or evil intentions. They drift because they become someone’s second priority.

In a CRO delivery model, priority is inferred. It shows up in who gets the fastest answers, where senior attention lands, and which decisions move without friction. And when governance is treated as a formality rather than a design choice, even well-funded, high-potential programs can slide to the bottom of a very long list.

A governance charter, when done well, is…

In a large pharmaceutical company the answer is straightforward: a Head of Clinical Operations runs a function of specialists. In a twenty-person biotech the title means something quite different, and the difference is where hiring decisions go wrong…

Succession planning sounds like a large-company concern. For an emerging biopharma sponsor, it is arguably more urgent, because the concentration risk is higher. When one person holds the operational history of a program, their departure is not an inconvenience. It is a material risk to the asset.

The concentration is easy to miss because it does not look like a single point of failure from the inside. The VP of Clinical Development knows…

AI readiness in clinical operations is not a technology question. It is a question of whether your processes, data and decision rights are clear enough for a machine to support them. Most sponsors who struggle with AI adoption are not short on tools. They are short on operational honesty about how their trials actually run.

I have spent nearly three decades inside CROs and sponsor organizations, and the pattern is…

Not all CROs are built for all programs.

Fit-for-purpose CRO selection is no longer a “nice to have”.  It is a core strategic decision that shapes execution, risk, and ultimately, outcomes.  Too often, sponsors default to brand recognition or broad “full-service” claims, but the real question is who can do your study exceptionally well.

The strongest partnerships are built by…

Selecting a CRO is often treated like casting a blockbuster:  choose the biggest name, assume the performance will follow.

After 25+ years inside CRO operations and working alongside sponsors, I can tell you—trial success is rarely determined by who is on the marquee.  It’s driven by what happens in the execution behind the scenes.

Here are five myths I still see shaping decisions and where they lead sponsors astray…

Most mentorship programs in clinical research organizations fail in the same way. A pairing is assigned, two calendar invitations are sent, three conversations happen, and the relationship quietly lapses. The program reports high participation and produces almost no development.

The failures are structural rather than personal. Four adjustments change the outcome.

Pair for the gap, not for seniority. The most useful mentor for a clinical trial manager learning vendor oversight is often…

Clinical trial teams are matrixed by design. The study lead coordinates contributors from medical, regulatory, biostatistics, data management, safety, and supply chain, none of whom report to them. This structure is sensible. It is also the source of most avoidable delay in clinical execution.

The delay rarely comes from disagreement. It comes from ambiguity about who decides. A question about whether a particular data discrepancy requires a query or a protocol deviation report circulates for eleven days, touching four functions, because nobody is certain the decision belongs to them and everybody is certain it might belong to someone else. The eventual answer…

Most sponsors treat CRO selection like procurement.

But your CRO should not be a vendor you source. Your CRO is the operations engine that runs your clinical program. How you select them determines how your trial actually runs:  how decisions get made, how problems surface, how fast you move when something breaks. Pick for price and capacity alone, and you have engineered the constraints you'll fight for the next three years…

Most CRO RFPs are built by biotech and emerging biopharma around capabilities and pricing grids. They ask what a CRO can do and what it costs. They rarely ask what happens when momentum falters, timelines stall, or the study runs aground on a risk no one charted.

The questions that actually determine success are the ones CROs would prefer not to answer directly. These are the questions that change the conversation…

Protocol amendments are among the most common events in clinical research and among the least well-led. The operational mechanics are usually handled competently. The team dynamics almost never are.

An amendment lands on a study team that has already built a rhythm. Sites are trained, systems are configured, monitors know their visits, and the data management plan reflects a specification that is about to change. The amendment invalidates…

ICH E6(R3) reframes good clinical practice around quality by design and proportionate, risk-based thinking. Most of the commentary has focused on what this means for processes and documentation. The more interesting question is what it asks of the people leading clinical programs.

The revision assumes judgment. It moves away from prescriptive uniformity and toward decisions that are reasoned, documented, and defensible in context. A sponsor is expected to…